Navigation Links
JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes
Date:6/18/2013

FRANKLIN LAKES, N.J. and NEW YORK, June 18, 2013 /PRNewswire/ -- JDRF and BD (Becton, Dickinson and Company) (NYSE: BDX) are accelerating the development of new products that combine BD's proprietary insulin infusion and glucose sensing technologies through a new collaboration announced today. This new, three-year commitment is an extension of existing JDRF-BD collaborations focused on type 1 diabetes (T1D).

Many patients with T1D not only take daily insulin via an insulin pump – requiring a catheter to be placed in the body for a number of days – but are also checking their glucose levels via a continuous glucose monitor (CGM), which also requires a catheter-like sensor to be placed in the body for a number of days.

While BD has been working to improve the products used for insulin infusion and CGM, the new collaboration with JDRF will enable additional research to develop a single optimized device that will perform both functions and eliminate the need and complexities of multiple in-dwelling catheters. The ability to perform these discrete metabolic actions automatically and accurately, with little patient intervention, defines the artificial pancreas concept.

"Providing the best tools that not only improve patient care, but ease the daily burden of managing diabetes are important goals for BD and JDRF," said Linda Tharby, President, BD Medical – Diabetes Care. "This latest collaboration with JDRF demonstrates both parties' commitment to improve patients' experiences and outcomes. Combining these novel technologies will address two key components of an advanced artificial pancreas system."

"As the world's largest charitable funder of type 1 diabetes research, JDRF is committed to advancing therapies that improve the lives of people living with this disease," said Jeffrey Brewer, President and Chief Executive Officer of JDRF. "We are excited to continue our collaboration with BD and support efforts to develop novel technologies enabling advanced artificial pancreas systems that will both measure glucose and administer insulin. Joining these capabilities into a single solution will address significant patient needs and help reduce the daily burden of managing type 1 diabetes."

T1D is an autoimmune disease in which the body's pancreas stops producing insulin, a hormone needed to turn food into energy. BD's culture of innovation and continuous improvement has enhanced the patient experience to help improve therapy and outcomes for people with diabetes worldwide. BD devices support earlier initiation and better adherence to prescribed therapies to help all diabetes patients live healthier lives.

About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

About JDRF
JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF's goal is to progressively remove the impact of T1D from people's lives until we achieve a world without T1D. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D.

As the largest charitable supporter of T1D research, JDRF is currently sponsoring $530 million in scientific research in 17 countries. In 2012 alone, JDRF provided more than $110 million to T1D research. More than 80 percent of JDRF's expenditures directly support research and research-related education. In 2012, Forbes magazine named JDRF one of its five All-Star charities, citing the organization's efficiency and effectiveness. For more information, please visit jdrf.org.Contacts:JDRFBD Tara Wilcox-Ghanoonparvar

Lindsay Roman (212) 479-7524

(201) 847-4312 twilcox-ghanoonparvar@jdrf.org

lindsay_roman@bd.com


'/>"/>
SOURCE BD (Becton, Dickinson and Company); JDRF
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sigma-Aldrich Accelerates Analytical Research and Extends Benefits of Fused-Core Particle Technology to All HPLC Users with the Launch of New Ascentis Express 5 Micron Particle by Supelco
2. In Observance of Veterans Day Reproductive Medicine Associates of New Jersey Extends "Helping Heroes Build Families" Program
3. Ansell Extends Antimicrobial Product Offering with New Non-latex Surgical Glove
4. New analog front end extends battery life of portable ECG equipment
5. AMRI Extends Long Term Supply Relationship with GE Healthcare
6. Prescription Eyewear Limited Extends Clear Leadership Position in Growing European Online Optical Market With Acquisition of Nordic Leader LensOn
7. Scottsdale Healthcare, TGen study shows Abraxane/gemcitabine combination extends survival of pancreatic cancer patients
8. Julphar Extends its Global Footprint With Official Inauguration of Julphar Ethiopia Manufacturing Facility
9. North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs
10. Ferring Pharmaceuticals Extends Its Heart to Heart Video Contest
11. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
Breaking Medicine News(10 mins):